SureNano Science Advances Obesity Drug GEP-44 in $200B Market

SureNano Science (CSE: SURE) (OTCQB: SURNF) is making strides in the obesity treatment market through its subsidiary GlucaPharm Inc., advancing GEP-44, a patented triple agonist peptide targeting GLP-1 and peptide YY receptors. As the global obesity and metabolic disease market expands, with projections exceeding $200 billion, SureNano is pursuing a differentiated approach focused on improved efficacy, tolerability, and delivery flexibility. The company positions itself as an emerging microcap player in a competitive GLP-1 landscape dominated by giants like Eli Lilly, Novo Nordisk, Amgen, and Pfizer, who are advancing next-generation therapies with new formulations and reduced-frequency dosing.

SureNano's strategy centers on preclinical innovation and alternative delivery technologies that may extend beyond metabolic diseases. The company acquired GlucaPharm Inc. to develop GEP44, aiming for improved tolerability and potential non-injectable delivery. Meanwhile, SureNano's initial business involves the sale and distribution of the SureNano™ surfactant, a ready-to-mix food-grade compound for nanoemulsions that enhance bioavailability and stability, licensed for Canada, Oklahoma, and Colorado.

Industry momentum continues as major pharma companies refine obesity and diabetes treatments, but SureNano's focus on broader platform opportunities and preclinical assets sets it apart. For investors tracking SURNF, the latest updates are available in the company's newsroom at https://ibn.fm/SURNF. The full press release can be viewed at https://ibn.fm/g3EkQ. This announcement was disseminated by InvestorWire, a specialized communications platform.